HCW Biologics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunotherapies that target inflammaging—the chronic, low-grade inflammation linked to age-related diseases. The company focuses on conditions including cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune disorders. HCW Biologics leverages two proprietary discovery platforms: TOBI™ (Tissue factOr-Based fusIon) and TRBC (T-cell Receptor β Chain constant region), which enable the design of multi-functional fusion molecules that simultaneously activate immune responses and target diseased cells. The company maintains a pipeline of over 50 molecules in development, with lead candidates currently advancing through clinical trials for oncology and autoimmune indications. HCW Biologics collaborates with key partners including Wugen Inc. for cell therapy manufacturing and maintains a joint venture with WY Biotech. Founded in 2018 and headquartered in Miramar, Florida, the company operates as a publicly traded entity pursuing immunotherapy innovation in the biopharmaceutical sector.